Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

MultiSurv: Long-term cancer survival prediction using multimodal deep learning

View ORCID ProfileLuís A. Vale-Silva, Karl Rohr
doi: https://doi.org/10.1101/2020.08.06.20169698
Luís A. Vale-Silva
Biomedical Computer Vision Group, BioQuant Center and Institute of Pharmacy and Molecular Biotechnology (IPMB), Heidelberg University, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Luís A. Vale-Silva
  • For correspondence: luisvalesilva@gmail.com
Karl Rohr
Biomedical Computer Vision Group, BioQuant Center and Institute of Pharmacy and Molecular Biotechnology (IPMB), Heidelberg University, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The age of precision medicine demands powerful computational techniques to handle high-dimensional patient data. We present MultiSurv, a multimodal deep learning method for long-term pan-cancer survival prediction. MultiSurv is composed of three main modules. A feature representation module includes a dedicated submodel for each input data modality. A data fusion layer aggregates the multimodal representations. Finally, a prediction submodel yields conditional survival probabilities for a predefined set of follow-up time intervals. We trained MultiSurv on clinical, imaging, and four different high-dimensional omics data modalities from patients diagnosed with one of 33 different cancer types. We evaluated unimodal input configurations against several previous methods and different multimodal data combinations. MultiSurv achieved the best results according to different time-dependent metrics and delivered highly accurate long-term patient survival curves. The best performance was obtained when combining clinical information with either gene expression or DNA methylation data, depending on the evaluation metric. Additionally, MultiSurv can handle missing data, including missing values and complete data modalitites. Interestingly, for unimodal data we found that simpler modeling approaches, including the classical Cox proportional hazards method, can achieve results rivaling those of more complex methods for certain data modalities. We also show how the learned feature representations of MultiSurv can be used to visualize relationships between cancer types and individual patients, after embedding into a low-dimensional space.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

L.A.V.S. was supported by an individual fellowship from the Chica and Heinz Schaller Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All necessary patient/participant consent and necessary approvals have been obtained to make the data publicly available. Data used in this study is not individually identifiable.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data used in this work are from The Cancer Genome Atlas (TCGA) program. The used datasets are available publicly from the National Cancer Institute (NCI) Genomic Data Commons (GDC) information system, accessible at the GDC Data Portal.

https://portal.gdc.cancer.gov/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted August 07, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
MultiSurv: Long-term cancer survival prediction using multimodal deep learning
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
MultiSurv: Long-term cancer survival prediction using multimodal deep learning
Luís A. Vale-Silva, Karl Rohr
medRxiv 2020.08.06.20169698; doi: https://doi.org/10.1101/2020.08.06.20169698
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
MultiSurv: Long-term cancer survival prediction using multimodal deep learning
Luís A. Vale-Silva, Karl Rohr
medRxiv 2020.08.06.20169698; doi: https://doi.org/10.1101/2020.08.06.20169698

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Informatics
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1752)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (658)
  • Epidemiology (10796)
  • Forensic Medicine (8)
  • Gastroenterology (587)
  • Genetic and Genomic Medicine (2946)
  • Geriatric Medicine (287)
  • Health Economics (533)
  • Health Informatics (1925)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (291)
  • HIV/AIDS (630)
  • Infectious Diseases (except HIV/AIDS) (12514)
  • Intensive Care and Critical Care Medicine (688)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2796)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1463)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (866)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2639)
  • Public and Global Health (5363)
  • Radiology and Imaging (1011)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)